Cargando…
Targeting the A(3) adenosine receptor to treat cytokine release syndrome in cancer immunotherapy
Cancer patients undergoing immunotherapy may develop cytokine release syndrome (CRS), an inflammatory cytokine storm condition, followed by neurotoxic manifestations and may be life-threatening. The current treatments for CRS successfully reduce the inflammatory response but may limit the anticancer...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363488/ https://www.ncbi.nlm.nih.gov/pubmed/30787591 http://dx.doi.org/10.2147/DDDT.S195294 |